Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Effect of the Haoqinqingdan decoction on damp–heat syndrome in rats with influenza viral pneumonia

Shi-Jin Zhang¹, Zhuo Chen², Guo-Wen Li³, Bo-Liang Wang⁴*

¹Department of Traditional Chinese Medicine, People’s Hospital of Zhengzhou, Zhengzhou 450012, China
²Pharmacy Department, Cancer Hospital Affiliated to Zhengzhou University, Zhengzhou 450008, China
³Department of Radiotherapy, Tangdu Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou450052, China
⁴Out-patient Department, Tangdu Hospital, The Second Affiliated Hospital of the Fourth Military Medical University, Xi’an 710038, China

ARTICLE INFO

Article history:
Received 10 May 2013
Received in revised form 15 June 2013
Accepted 15 July 2013
Available online 20 August 2013

Keywords:
Haoqinqingdan decoction
Ribavirin
Damp–heat syndrome
Influenza virus
Wistar rat

ABSTRACT

Objective: To investigate the effect of Chinese medicine prescription–Haoqinqingdan decoction on damp–heat syndrome in rats with influenza viral pneumonia and its influence on the immune function. Methods: A total of 48 Wistar rats were randomly divided into the normal control group, the damp–heat syndrome model group, the Haoqinqingdan decoction group (high, medium and low dose group) and the ribavirin group. The body temperature and weight of rats in each group were recorded after modeling. After treatment for 6 d, the concentration of T lymphocyte subgroup (CD3⁺CD4⁺, CD3⁺CD8⁺) was determined by flow cytometry. The OD value of IFN-γ/IL-4 was detected by double-antibody sandwich ELISA method, and its concentration was acquired through conversion. Results: After modeling, the temperature and weight of rats in each modeling group showed the increasing trend (P<0.01). From the second day of treatment, there was significant difference in the body mass between groups, and the rat weight of the control group was higher than in the modeling group (P<0.05 or 0.01). With the advances of treatment, only the temperature in the medium and high dose Haoqinqingdan decoction groups declined significantly (P<0.05). After treatment, the CD4⁺/CD8⁺ ratio of the damp–heat syndrome model group decreased more significantly compared with the control group. Elevated CD3⁺CD8⁺ percentages and declined CD4⁺/CD8⁺ ratios can be observed in the low dose group and ribavirin group (P<0.05). Moreover, the CD3⁺CD4⁺ percentage of ribavirin group was lower than in the control group (P<0.05). After treatment, the IFN-γ and IFN-γ/IL-4 levels in the peripheral blood of rats in the damp–heat syndrome group were obviously higher than in the control group (P<0.05). Conclusions: Compared with ribavirin, the high dose Haoqinqingdan decoction can improve the ratio of T lymphocyte subgroup and Th1/Th2 cell balance more effectively.

1. Introduction

Sourced from “Renewed Popular Treatise on Febrile Diseases” Haoqinqingdan decoction is a famous prescription founded by Gen–Chu Yu, a famous doctor in Qing dynasty[1]. This prescription was designed originally for Shaoyang damp–heat syndrome and proved to have good efficacy in clinical practice[2]. The damp–heat syndrome is an acute exogenous febrile disease caused by pathogenic dampness. The causes of damp–heat syndrome are multifactorial, including not only environmental factors, but also autoimmune function and pathogenic microorganism[3]. Viral infection is one of the common causes of damp–heat syndrome. It was found that people tend to have viral damp–heat syndrome in hot and humid environment, and
influenza virus infection is most common\cite{4}. Due to the limitation of Western medicine and the hysteresis of vaccine development, the treatment of this disease is not satisfactory. However, traditional Chinese medicine shows its unique advantages in the treatment of this disease. A study found that Haoqinqingdan decoction can decrease the mRNA level of NF-κB and the percentage of Th1/Th2 through decreasing the expression of TLR2, decrease lung index and improve pathological change\cite{5}. On the basis of related studies, we illustrated the advantages of Haoqinqingdan decoction in treating this disease and its role in regulating immunity through the comparison between the high, medium and low dose Haoqinqingdan decoction groups and the ribavirin group, which would provide basis for differential traditional Chinese medicine treatment of upper respiratory viral infection\cite{6}.

2. Materials and methods

2.1. Experimental materials

Experimental animals and strains: 60 Wistar rats in SPF grade with the weight of 180–200 g; the influenza virus A1 (H1N1) FM1 strains were provided by the National Institute for the Control of Pharmaceutical and Biological Products. Medicine: Haoqinqingdan decoction. Composition: 10 g Artemisia annua L, 15 g baikal skullcap root, 6 g tangerine peel, 10 g rhizoma Pinelliae praeparatum, 10 g Fructus auranti, 10 g Bambusae caulis im taeniam, 30 g talcum, 15 g Folium isatidis and 6 g Glycyrrhiza uralensis. The decoction method referred to the Great Dictionary of TCM formulas. The medicine was concentrated to 1 g/mL and saved in the refrigerator at 4 ℃. Positive control medicine: ribavirin purchased from the Department of Pharmacy of Zhengzhou Central Hospital.

2.2. Modeling and grouping

According to the method reported in the study\cite{7}, 48 rats were randomly divided into 6 groups with 8 rats in each group, namely, the normal control group, the damp–heat syndrome model group, the high, medium and low dose Haoqinqingdan decoction groups (the high, medium and low dose groups for short) and the ribavirin group. The modeling started after 1d adaptive feeding. The modeling groups were raised by high-fat diet every day, while the normal group was given normal diet. On the tenth day of modeling, the rats in the modeling groups were infected by the H1N1 virus through nasal drip. 24 h after viral infection, the rats in modeling groups were put into the artificial temperature chamber at 32±0.5 ℃, 55%–60% air humidity for 3 h. These rats were exposed in this environment for 3h every other day with a total heat exposure for three times. The normal control group and modeling group were raised separately. The body weight and temperature of rats were measured at 9 am every day after modeling.

On the 17th day after modeling, intragastric administration once a day was performed for each treatment group (high, medium and low dose groups and ribavirin group). The dosage of Haoqinqingdan decoction was calculated according to the body surface area of human and rat. The doses of high, medium and low groups were 36.92 mg/kg/d, 18.46 mg/kg/d and 9.23 mg/kg/d, respectively. The ribavirin dose was 70 mg/kg/d. The normal control group and damp–heat syndrome model group were intragastrically administrated by normal saline.

2.3. Detection of T cell subgroup and cytokine level of rats in each group

After medication for 6 d, eyeballs were extracted for blood, and food and water were prohibited 4 h before the blood extraction. A total of 0.5 mL blood was added into the anticoagulant tube and fully mixed. Detection of T lymphocyte subgroup was finished in the same day. The serum was separated after blood standing and then was used for cytokine detection.

Detection of T lymphocyte subgroup: 0.5 mL heart blood was taken from the rats. The number and percentage of each T lymphocyte subgroup was measured by flow cytometry using three kinds of antibodies labeled by different fluorescent dyes. The operative procedures were strictly in accordance with the instruction.

Detection of the cytokine level (IFN-γ/IL-4): about 1mL supernatant was taken from rats. Double–antibody sandwich ELISA method was used to detect the concentration of cytokine. The curve was drawn using the concentration of the standard preparation as the X-axis and OD value as the Y-axis. The concentration of the specimen can be found in the curve by its OD value. IL–4/IFN–γ = concentration in the standard curve × dilution multiple.

2.4. Statistics analysis

ANOVA and t test were used for experimental data. Multi–group comparisons used One–Way ANOVA. Results were considered to be statistically significant when P<0.05. SPSS 16.0 software was used for statistical analysis.

3. Results

3.1. Temperature and weight changes of rats in each group after modeling

From the first day to the 14th day after modeling, the weight of rats in each experimental group and control group
increased significantly ($P<0.01$), but the rat weight difference among groups was not significant at the same time ($P>0.05$). Changes of body temperature: From the first day to the 14th day after modeling, the temperature change of the control group was not significant ($P>0.05$), but the rat temperature of the modeling groups (the damp–heat syndrome model group, the Haoqingdingan decoction groups and the ribavirin group) showed the trend of increasing ($P<0.01$), and the temperature comparison at the same time showed that the temperature of rats in the modeling groups was significantly higher than in the control group on the 14th day of modeling ($P<0.05$, Table 1, 2).

### 3.2. Temperature and weight changes of rats in each group after treatment

The 17th day after modeling was regarded as the first day of treatment. The intragastric administration was given

| Table 1 | Body weight changes of rats in each group after modeling ($\text{mean} \pm \text{SD}, \text{g}$). |
|---------|-----------------------------------------------------------------------------------------------|
| Group   | 1 d | 7 d | 10 d | 14 d | $F$ | $P$ |
| Control | 192.4±9.1 | 248.8±7.6 | 260.6±6.5 | 279.8±8.5 | 177.3 | 0.00 |
| Damp–heat syndrome model | 197.5±9.0 | 252.7±10.5 | 267.3±7.8 | 270.7±6.5 | 126.2 | 0.00 |
| High dose group | 191.4±11.3 | 247.8±6.7 | 264.2±5.8 | 268.1±7.8 | 108.5 | 0.00 |
| Medium dose group | 196.7±8.6 | 254.1±10.0 | 270.6±8.3 | 272.3±7.1 | 115.4 | 0.00 |
| Low dose group | 187.8±8.2 | 246.4±8.2 | 263.1±9.0 | 266.4±8.3 | 120.9 | 0.00 |
| Ribavirin | 190.6±7.4 | 250.3±7.9 | 268.9±8.2 | 271.6±9.7 | 132.7 | 0.00 |

| $F$ | 0.7 | 0.2 | 1.1 | 1.2 |
| $P$ | 0.60 | 0.91 | 0.40 | 0.24 |

| Table 2 | Temperature changes of rats in each group after modeling ($\text{mean} \pm \text{SD}, ^{\circ}\text{C}$). |
|---------|-----------------------------------------------------------------------------------------------|
| Group   | 1 d | 7 d | 10 d | 14 d | $F$ | $P$ |
| Control | 37.7±0.2 | 37.6±0.3 | 37.8±0.2 | 37.8±0.3 | 0.6 | 0.62 |
| Damp–heat syndrome model | 37.8±0.2 | 37.9±0.3 | 38.3±0.4 | 38.9±0.5 | 5.9 | 0.02 |
| High dose group | 37.8±0.3 | 38.0±0.3 | 38.3±0.5 | 39.0±0.5 | 4.8 | 0.03 |
| Medium dose group | 37.7±0.3 | 37.9±0.4 | 38.2±0.4 | 39.0±0.4 | 7.0 | 0.01 |
| Low dose group | 37.9±0.4 | 38.1±0.3 | 38.5±0.3 | 39.2±0.5 | 7.1 | 0.01 |
| Ribavirin | 37.8±0.4 | 38.0±0.3 | 38.4±0.4 | 39.1±0.4 | 7.0 | 0.01 |

| $F$ | 0.6 | 1.5 | 1.6 | 6.0 |
| $P$ | 0.62 | 0.29 | 0.27 | 0.02 |

| Table 3 | Weight changes of rats in each group after treatment ($\text{mean} \pm \text{SD}, \text{g}$). |
|---------|-------------------------------------------------------------------------------|
| Group   | 1 d | 2 d | 3 d | 4 d | 5 d | 6 d | $F$ | $P$ |
| Control | 287.6±7.3 | 293.8±9.0 | 299.4±8.1 | 302.5±7.8 | 304.4±6.8 | 307.8±9.2 | 3.5 | 0.04 |
| Damp–heat syndrome model | 271.1±8.5 | 270.0±8.3 | 269.0±8.8 | 267.5±9.0 | 267.9±10.2 | 268.1±9.7 | 0.1 | 0.98 |
| High dose group | 268.0±7.8 | 269.5±7.9 | 270.8±8.3 | 271.9±7.3 | 272.8±8.4 | 274±6.8 | 0.2 | 0.94 |
| Medium dose group | 271.6±8.1 | 272.1±8.2 | 272.9±7.5 | 273.3±8.3 | 273.6±8.4 | 274.2±8.7 | 0.3 | 0.91 |
| Low dose group | 267.5±8.5 | 267.8±8.0 | 270.2±8.9 | 270.8±8.8 | 271.5±9.0 | 272.0±8.9 | 0.2 | 0.97 |
| Ribavirin | 271.9±6.9 | 272.0±7.2 | 272.2±7.3 | 272.3±6.8 | 272.5±7.1 | 272.9±7.4 | 0.2 | 0.97 |

| $F$ | 2.5 | 4.1 | 5.9 | 7.5 | 7.9 | 8.7 |
| $P$ | 0.09 | 0.02 | <0.01 | <0.01 | <0.01 | <0.01 |

| Table 4 | Temperature changes of rats in each group after treatment ($\text{mean} \pm \text{SD}, ^{\circ}\text{C}$). |
|---------|-------------------------------------------------------------------------------|
| Group   | 1 d | 2 d | 3 d | 4 d | 5 d | 6 d | $F$ | $P$ |
| Control | 37.7±0.3 | 37.6±0.5 | 37.8±0.5 | 37.9±0.6 | 37.8±0.4 | 37.8±0.5 | 0.2 | 0.98 |
| Damp–heat syndrome model | 38.8±0.4 | 38.9±0.4 | 39.0±0.6 | 39.2±0.5 | 38.9±0.5 | 38.8±0.6 | 0.4 | 0.80 |
| High dose group | 39.0±0.3 | 38.8±0.5 | 38.6±0.4 | 38.3±0.6 | 38.1±0.5 | 37.8±0.4 | 3.7 | 0.03 |
| Medium dose group | 39.1±0.5 | 38.9±0.4 | 38.8±0.6 | 38.7±0.4 | 38.5±0.6 | 38.1±0.5 | 3.5 | 0.04 |
| Low dose group | 39.2±0.3 | 39.1±0.5 | 38.9±0.4 | 38.9±0.5 | 38.7±0.6 | 38.5±0.5 | 1.2 | 0.38 |
| Ribavirin | 38.9±0.4 | 38.9±0.5 | 38.8±0.5 | 38.7±0.3 | 38.7±0.3 | 38.6±0.4 | 0.5 | 0.76 |

| $F$ | 7.3 | 3.8 | 2.7 | 3.2 | 2.2 | 3.2 |
| $P$ | <0.01 | 0.03 | 0.08 | 0.04 | 0.12 | 0.04 |
to the Haoqinqingdan decoction group and the ribavirin group, while the normal control group and the damp–heat syndrome model group were intragastrically administrated by normal saline. The results indicated that the weight of rats in each modeling group slowly increased, but not obviously. The group comparison indicated that from the second day of treatment, the weight difference among each group was significant, and the body weight of rats in the control group was obviously higher than in the modeling groups \(P<0.05\) or \(0.01\). With the advances of treatment, obvious temperature decrease can only be observed in the medium and high dose Haoqinqingdan decoction groups \(P<0.05\), Table 3, 4).

### 3.3. Comparison of T lymphocyte subgroup and IFN-\(\gamma\)/\(IL-4\) level

After treatment for 6 days, the CD3\(^+\)/CD4\(^-\)/CD8\(^-\) ratio in the damp–heat syndrome model obviously decreased compared with the normal control group, but the percentage of CD3\(^+\)/CD8\(^-\) increased \(P<0.05\). Increased CD3\(^+\)/CD8\(^-\) percentage and decreased CD4\(^+\)/CD8\(^-\) ratio can be observed in the low dose group and ribavirin group \(P<0.05\). Moreover, the CD3\(^+\)/CD4\(^+\) percentage of the ribavirin group was lower than in the control group \(P<0.05\), Table 5. The IFN-\(\gamma\) and IFN-\(\gamma\)/\(IL-4\) levels in the peripheral blood of rats in the damp–heat syndrome model were obviously higher than in the control group \(P<0.05\), Table 6.

#### Table 5
Comparison of T lymphocyte subgroup in each group (mean±SD).

| Group                  | CD3\(^+\)/CD4\(^+\) (%) | CD3\(^+\)/CD8\(^-\) (%) | CD4\(^+\)/CD8\(^-\) (%) |
|------------------------|--------------------------|--------------------------|--------------------------|
| Control                | 7.50±1.7                 | 24.1±1.3                 | 3.1±0.4                  |
| Damp–heat syndrome     | 62.5±4.1 \(^*\)          | 28.2±2.3 \(^*\)          | 2.2±0.2 \(^*\)          |
| High dose group        | 74.5±2.6                 | 24.5±2.1                 | 3.0±0.3                  |
| Medium dose group      | 73.9±2.5                 | 24.9±2.1                 | 2.9±0.3                  |
| Low dose group         | 73.0±3.1                 | 25.4±3.7 \(^*\)          | 2.8±0.4 \(^*\)          |
| Ribavirin              | 72.8±4.3 \(^*\)          | 25.6±3.0 \(^*\)          | 2.8±0.2 \(^*\)          |

\(^*\): Compared with the control group, \(P<0.01\); \(^*\): Compared with the control group, \(P<0.05\).

#### Table 6
Comparison of Th1/Th2 level in each group (mean±SD).

| Group                  | IFN-\(\gamma\) (ng/L) | IL-4 (ng/L) | IFN-\(\gamma\)/IL-4 |
|------------------------|-----------------------|-------------|---------------------|
| Control                | 7 454.3±328.9         | 3 695.8±328.5 | 2.0                 |
| Damp–heat syndrome     | 7 996.3±156.4 \(^*\) | 3 506.2±187.9 | 2.3 \(^*\)          |
| High dose group        | 7 505.8±286.7         | 3 490.8±217.3 | 2.1                 |
| Medium dose group      | 7 497.4±202.8         | 3 517.9±231.7 | 2.1                 |
| Low dose group         | 7 488.5±227.0         | 3 548.6±184.6 | 2.1                 |
| Ribavirin              | 7 483.6±226.5         | 3 601.4±198.2 | 2.0                 |

\(^*\): Compared with the control group, \(P<0.05\).

### Discussion

In modern medicine, respirovirus is a kind of virus invading into the human body through respiratory tract and causing respiratory tract and/or systemic infection. In most circumstances, this kind of virus would infect host cell and induce immune response after entering human body through respiratory tract\([8]\). Due to the high mutation rate, this kind of virus (such as influenza virus, parainfluenza virus, coronavirus and some enteric viruses) often brings great difficulty to clinical diagnosis and treatment in clinical practice\([9,10]\). The treatment of this kind of virus is mainly symptomatic treatment in modern medicine. Despite of the occurrence of many broad–spectrum antiviral agents and vaccine, this kind of infection can hardly be radically cured for the high variability and drug resistance of virus\([11–14]\). In the treatment of these diseases, traditional Chinese medicine focuses on the relationship between virus, organism and medicine rather than the virus itself.

Respiratory viral infection and its pathogenesis are closely related to the immune state of organism. This kind of infection belongs to the damp–heat febrile disease, because its clinical manifestation and occurrence season and region are very similar to the defensive qi & body surface and qiophase syndrome of febrile disease\([15]\). Having the function of Qingdan dampness, and regulating stomach and dissipating phlegm, Haoqinqingdan decoction is a representative prescription for clearing heat and eliminating dampness. Febrile disease theory holds that clearing heat and eliminating dampness method has the function of guiding qi downward, activating spleen, regulating stomach, promoting diuresis, clearing heat and dissipating dampness, which is suitable for damp–heat febrile disease\([16]\). The experimental results of our study indicated that Haoqinqingdan decoction can reverse the decline tendency of CD4\(^+\)/CD8\(^-\) ratio caused by the synthetic action of damp–heat environment and viral infection, making the CD4\(^+\)/CD8\(^-\) ratio close to the normal control group. In the comparison of Th1/Th2 cytokine (IFN-\(\gamma\)/IL-4) level, after treated by Haoqinqingdan decoction for 6 days, the IFN-\(\gamma\) and IFN-\(\gamma\)/IL-4 levels in the peripheral blood of rats in the damp–heat syndrome model group was obviously higher than in the control group \(P<0.05\), Table 6.

In modern medicine, obvious decline
of temperature can only be observed in the medium and high dose Haoqinqingdan decoction groups \( (P<0.05) \), and the effect of decreasing rat temperature was not obvious in low dose Haoqinqingdan decoction group and the ribavirin group \( (P>0.05) \), which indicated that the therapeutic effect of Haoqinqingdan decoction on fever caused by influenza virus was notable\(^{[18-20]}\). In the aspect of weight, although the effect of ribavirin was poorer than the medium and high dose Haoqinqingdan decoction, which indicated that damp–heat syndrome had great impact on the dietary intake and metabolism of rats, and this impact can hardly recovered in a short time. It was also found that in regulation of the balance of T cell subset \((\text{CD}4^+/\text{CD}8^+\)\), the therapeutic effect of ribavirin was poorer than the medium and high dose Haoqinqingdan decoction, but was close to the low dose Haoqinqingdan decoction, which indicated that ribavirin has a certain effect on the treatment of damp–heat syndrome caused by influenza virus, but is not superior to Haoqinqingdan decoction.

**Conflict of interest statement**

We declare that we have no conflict of interest.

**References**

[1] Mo RG, Han XM, Yin X, Wang GZ, Dong J. Experimental study on the inhibiting flu virus action of Haoqinqingdan decoction. *Trad Chin Med Res* 2005; **18**(5): 16–20.

[2] Han XM, Ma CJ, Mo RG, Qian ZH, Ren CX, Tan YQ. On new application of ancient prescriptions starting with clinical and experimental research of haoqinqingdan decoction. *Trad Chin Med Res* 2011; **24**(7): 1–3.

[3] He HH, Shen H, Zheng K. Observation of the curative effect of qingchahanghuashi recipe for treating active ulcerative colitis of inner–accumulation of damp–heat syndrome. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2012; **32**(12): 1598–601.

[4] Yang CJ, Liu HW, Wang LC. Study on the differential gene expressions of chronic hepatitis B patients of gan depression pi deficiency syndrome and pi–wei damp–heat syndrome. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2012; **32**(8): 1032–1037.

[5] Pan Y, Luo BD, Lin PZ, Liu Y, Wan WR, Guo JQ. The mechanism of signal extension in Haoqinqingdan decoction immunity activity in damp–heat syndrome of pneumonia disease infected by influenza virus. *Zhanghua Yu Fang Yi Xue Za Zhi* 2010; **44**(7): 612–616.

[6] Poon PM, Wong CK, Fung KP, Fong CY, Wong EL, Lau JT, et al. Immunomodulatory effects of a traditional Chinese medicine with potential antiviral activity: a self–control study. *Am J Chin Med* 2006; **34**(1): 13–21.

[7] Su LX, Tang ZH, Liu Y, Wan WR, Guo JQ, Luo BD, et al. Effects of hao qin qing dan decoction and jade screen powder on changes of T–lumphocyte subsets and serum Th1/Th2 cell factors in mouse with damp–heat syndrome infected by influenza virus. *Liaoning J Trad Chin Med* 2010; **37**(3): 544–546.

[8] Job ER, Bottazzi B, Gilbertson B, Edenborough KM, Brown LE, Mantovani A, et al. Serum amyloid p is a sialylated glycoprotein inhibitor of influenza a viruses. *PLoS One* 2013; **8**(3): e59623.

[9] Bicer S, Giray T, Çol D, Erdag GC, Vitrinel A, Güröl Y, et al. Virological and clinical characterizations of respiratory infections in hospitalized children. *Ital J Pediatr* 2013; **39**: 22.

[10] Walther T, Karamanska R, Chan RW, Chan MC, Jia N, Air G, et al. Glycomic analysis of human respiratory tract tissues and correlation with influenza virus infection. *PLoS Pathog* 2013; **9**(3): e1003223.

[11] Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. *Cochrane Database Syst Rev* 2013; **2**: CD000364.

[12] Castilla J, Martínez–Baz I, Martínez–Artola V, Reina G, Pozo F, García Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. *Euro Surveill* 2013; **18**(5): 20388.

[13] Soltanialvar M, Goodarzi R, Akbarnejad F. Genetic analysis of polymerase complex (PA, PB1 and PB2) genes of H9N2 avian influenza viruses from Iran (1999 to 2009). *Asian Pac J Trop Biomed* 2012; **2**(11): 858–862.

[14] Afzal F, Saeed A, Sharif MA, Ayub N, Hassan S. Pathogenicity of avian influenza virus H5N1 2007 isolates from Pakistan. *Asian Pac J Trop Biomed* 2012; **2**(Suppl 1): S380–S382.

[15] Su LX. Curative effect and mechanism of wormwood and scutellaria gallbladder clearing decoction cured viral upper respiratory tract infection. *Guangzhou Univ Chin Med* 2010.

[16] Xu JQ, Wang MZ, Xu ZJ. *Pharmacology of traditional Chinese medical formulae*. Shanghai: Shanghai Science and Technology Press, 1994: 47–48.

[17] Pan Y, Antagonism effects and signal transduction path of Hao Qin Qing Dan decoction on damp–heat syndrome of pneumonia disease infected by influenza virus. *Southern Med J* 2009.

[18] Huang Y, Shi ZY. 48 cases of exogenous fever treated by Haoqin Qingdan Decoction with addition and subtraction method. *J Guangzhou Univ Trad Chin Med* 1997; **14**(2): 79–81.

[19] Su MX, Fang JY. 54 cases of viral fever treated by Haoqin Qingdan Decoction. *J Pract Trad Chin Internal Med* 1999; **13**(2): 25.

[20] Chen YH, Zhong JX, Wu ZB, Lin XD, Liu Y, Su LX, et al. Therapeutic effect of Haoqin Qingdan Decoction combined with Tanreqing on influenza virus fever. *Hubei J TCM* 2010; **32**(3): 45–46.